A sophora japonica composition for treating intestinal inflammation and protecting intestinal mucosa, and a preparation method and application thereof

Abstract

The application discloses a sophora japonica composition for refractory enteritis and a preparation method and application thereof. The sophora japonica composition for refractory enteritis comprises the following components: sophora japonica, dried orange peel, panax notoginseng, momordica grosvenori and lycoris radiata, and the sophora japonica composition for refractory enteritis is obtained by fermenting plant lactobacillus. The sophora japonica composition for refractory enteritis of the application can obviously increase the amount of duhrlactobacillus, lactobacillus and bifidobacterium and reduce the amount of clostridium in the process of treating inflammatory enteritis; can effectively inhibit the inflammation of colitis, and the mRNA level of inflammatory cytokines TNF-alpha, IL-22, IL-1beta and IL-6 is obviously reduced. The sophora japonica composition can obviously inhibit intestinal inflammation, promote the metabolism of intestinal short-chain fatty acids, increase the thickness of intestinal mucosa, and has obvious curative effects on intestinal microecological homeostasis of inflammatory bowel disease, intestinal inflammation and protection of intestinal mucosa.

Description

TECHNICAL FIELD

[0001] The present application relates to the field of traditional Chinese medicine, and particularly relates to a sophora fruit composition for treating intestinal inflammation and protecting intestinal mucosa, and a preparation method and application thereof. BACKGROUND

[0002] The human microbiome is a complex and large system, which contains microorganisms such as bacteria, fungi, viruses and archaea. The intestinal microorganisms of the human body closely interact with the host through metabolism and immune tolerance, for example, synthesis of short-chain fatty acids and essential vitamins, regulation of the intestinal immune system and maintenance of the mucosal barrier.

[0003] There are various types of intestinal inflammation, such as ulcerative colitis, radiation enteritis, intestinal inflammation caused by infection, immune abnormalities, radiation, etc. The research on intestinal microorganisms and their correlation with gastrointestinal diseases, especially intestinal inflammation, has been widely carried out, which provides a new perspective for the etiology research and non-invasive diagnosis of gastrointestinal diseases. The intestinal symbiotic microorganisms establish the connection between the environment and the intestinal tract, and therefore the change in the functional composition of the intestinal microbiome, i.e. the ecological imbalance, plays a crucial role in the occurrence and development of intestinal inflammation. Therefore, it is particularly important to invent a composition for regulating the intestinal microecology for the treatment of intestinal inflammation. SUMMARY

[0004] In order to overcome the shortcomings of the prior art, the first object of the present application is to provide a sophora fruit composition for treating intestinal inflammation and protecting intestinal mucosa. The sophora fruit composition for treating intestinal inflammation and protecting intestinal mucosa provided by the present application can significantly inhibit intestinal inflammation, increase the thickness of intestinal mucosa, and promote the metabolism of short-chain fatty acids in the intestine. The curative effect on the intestinal microecological homeostasis of inflammatory bowel disease, intestinal inflammation and protection of intestinal mucosa is remarkable.

[0005] The second object of the present application is to provide a preparation method of the above-mentioned sophora fruit composition for treating intestinal inflammation and protecting intestinal mucosa.

[0006] The third object of the present application is to provide an application of the above-mentioned sophora fruit composition for treating intestinal inflammation and protecting intestinal mucosa.

[0007] The objects of the present application are achieved by adopting the following technical solutions:

[0008] The sophora fruit composition for treating intestinal inflammation and protecting intestinal mucosa comprises the following components: sophora fruit, dried tangerine or orange peel, panax notoginseng, momordica grosvenori and flos lonicerae japonicae, wherein the components are fermented by plant lactobacillus to obtain the sophora fruit composition for treating intestinal inflammation and protecting intestinal mucosa.

[0009] Further, the weight ratio of the sophora fruit, dried tangerine or orange peel, panax notoginseng, momordica grosvenori and flos lonicerae japonicae is (4-6) :(2-5) :(1-2) :(0.5-1) :(1-3).

[0010] Further, the weight ratio of the sophora, dried tangerine or orange peel, panax notoginseng, momordica grosvenori and day lily is 5:3:1.5:0.5:2.

[0011] Further, the preparation method of the fermented lactobacillus plantarum comprises the following steps: culturing and fermenting the lactobacillus plantarum to obtain the fermented lactobacillus plantarum.

[0012] Further, the lactobacillus plantarum is cultured and fermented in a liquid culture medium, and the liquid culture medium comprises the following components: peptone, corn starch, yeast powder, dipotassium hydrogen phosphate, sodium acetate, diammonium hydrogen citrate, magnesium sulfate and manganese sulfate.

[0013] The preparation method of the sophora composition for treating intestinal inflammation and protecting intestinal mucosa according to any one of the above, comprises the following steps: inoculating the fermented lactobacillus plantarum into a fermentation substrate containing sophora, dried tangerine or orange peel, panax notoginseng, momordica grosvenori and day lily for fermentation to obtain the traditional Chinese medicine composition for preventing and treating intestinal diseases.

[0014] Further, the inoculation amount of the fermented lactobacillus plantarum is 0.5-3wt%.

[0015] Further, the fermentation substrate comprises the following components by weight percentage: the composition of sophora, dried tangerine or orange peel, panax notoginseng, momordica grosvenori and day lily 80-98%, lecithin 1.9-17.5%, rhamnose glycosidase 0.01-1%, dipotassium hydrogen phosphate 0.03-1% and magnesium sulfate 0.01-0.5%.

[0016] Further, the fermentation conditions of inoculating the fermented lactobacillus plantarum into the fermentation substrate containing sophora, dried tangerine or orange peel, panax notoginseng, momordica grosvenori and day lily are as follows: mixing under 30-60% moisture, uniformly mixing and then fermenting at 25-35℃ for 5-7 days.

[0017] The sophora composition for treating intestinal inflammation and protecting intestinal mucosa according to any one of the above is applied to the preparation of health care products or drugs for treating intestinal inflammation and protecting intestinal mucosa.

[0018] Compared with the prior art, the present application has the following advantages:

[0019] (1) The sophora japonica composition for treating intestinal inflammation and protecting intestinal mucosa of the present application can significantly increase the amount of Dubosiella, Lactobacillus and Bifidobacterium and reduce the amount of Clostridia in the process of treating inflammatory bowel disease; can effectively inhibit the inflammation of colitis, and the mRNA levels of inflammatory cytokines TNF-α, IL-22, IL-1β and IL-6 are significantly reduced. The sophora japonica composition for treating intestinal inflammation and protecting intestinal mucosa can significantly inhibit intestinal inflammation, increase the thickness of intestinal mucosa, promote the metabolism of short-chain fatty acids in the intestine, and improve the absorption capacity of the intestine.

[0020] (2) The preparation method of the sophora japonica composition for treating intestinal inflammation and protecting intestinal mucosa of the present application is to ferment the composition of sophora japonica, pericarpium citri reticulatae, panax notoginseng, momordica grosvenori and flos lonicerae japonicae by lactobacillus plantarum, which does not need complex process, can be used for large-scale production, and reduces cost and saves manpower.

[0021] (3) The sophora japonica composition for treating intestinal inflammation and protecting intestinal mucosa of the present application is applied to the preparation of health care products and drugs for intestinal inflammation and protection of intestinal mucosa. The sophora japonica composition for treating intestinal inflammation and protecting intestinal mucosa can effectively inhibit the inflammation of colitis, and has significant curative effect on intestinal microecological homeostasis, intestinal inflammation and protection of intestinal mucosa of inflammatory bowel disease, and is applied to the field of health care products and drugs for treating inflammatory bowel disease. BRIEF DESCRIPTION OF DRAWINGS

[0022] Figure 1 The expression amount of the inflammatory factor interleukin 1β (IL-1β) gene of each group;

[0023] Figure 2 The expression amount of the inflammatory factor interleukin 6 (IL-6) gene of each group;

[0024] Figure 3 The expression amount of the tumor necrosis factor α (TNF-α) gene of each group;

[0025] Figure 4 The content data graph of short-chain fatty acids acetic acid in the intestine of each group;

[0026] Figure 5 The content data graph of short-chain fatty acids propionic acid in the intestine of each group;

[0027] Figure 6 The content data graph of short-chain fatty acids butyric acid in the intestine of each group;

[0028] Figure 7 The content data graph of Lactobacillus in the intestine of each group;

[0029] Figure 8 a content data graph of Dubosiella in the intestines of each group;

[0030] Figure 9 a content data graph of Clostridia in the intestines of each group;

[0031] Figure 10 a permeability detection data graph of each group. DETAILED DESCRIPTION

[0032] For the purpose of promoting the understanding of the present application, the present application will be more fully described by reference to the following drawings. The preferred embodiments of the present application are shown in the drawings. However, the present application can be embodied in many different forms and should not be construed as limited to the embodiments set forth herein. Rather, these embodiments are provided so that this disclosure will be thorough and complete, and fully convey the scope of the application to those skilled in the art.

[0033] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this application belongs. The terminology used in the description of the application herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the application. As used herein, the term "and / or" includes any and all combinations of one or more of the associated listed items.

[0034] A flos sophorae composition for treating intestinal inflammation and protecting intestinal mucosa, comprising the following components: flos sophorae, pericarpium citri reticulatae, panax notoginseng, momordica grosvenori and flos lonicerae japonicae, wherein the components are fermented by fermented plant lactobacillus to obtain the flos sophorae composition for treating intestinal inflammation and protecting intestinal mucosa.

[0035] The flos sophorae composition for treating intestinal inflammation and protecting intestinal mucosa of the present application can significantly increase the amount of Dubosiella, Lactobacillus and Bifidobacterium and reduce the amount of Clostridia in the process of treating inflammatory bowel disease; can effectively inhibit the inflammation of colitis, and the mRNA levels of inflammatory cytokines TNF-α, IL-22, IL-1β and IL-6 are significantly reduced. The flos sophorae composition for treating intestinal inflammation and protecting intestinal mucosa can significantly inhibit intestinal inflammation, increase the thickness of intestinal mucosa, and promote the metabolism of short-chain fatty acids in the intestine.

[0036] In one embodiment, the weight ratio of flos sophorae, pericarpium citri reticulatae, panax notoginseng, momordica grosvenori and flos lonicerae japonicae is (4-6):(2-5):(1-2):(0.5-1):(1-3).

[0037] In one of the embodiments, the weight ratio of the sophora japonica fruit, the citrus reticulata peel, the panax notoginseng, the momordica grosvenori and the flos lonicerae japonicae is 5:3:1.5:0.5:2.

[0038] In one of the embodiments, the preparation method of the fermented lactobacillus plantarum comprises the following steps: culturing and fermenting the lactobacillus plantarum to obtain the fermented lactobacillus plantarum.

[0039] In one of the embodiments, the lactobacillus plantarum is cultured and fermented in a liquid culture medium, and the liquid culture medium comprises the following components: peptone, corn starch, yeast powder, dipotassium hydrogen phosphate, sodium acetate, diammonium hydrogen citrate, magnesium sulfate and manganese sulfate.

[0040] In one of the embodiments, the liquid culture medium comprises the following components: peptone 10.0 g / L, corn starch 5.0 g / L, yeast powder 5.0 g / L, dipotassium hydrogen phosphate 2.0 g / L, sodium acetate 5.0 g / L, diammonium hydrogen citrate 2.0 g / L, magnesium sulfate 0.2 g / L and manganese sulfate 0.054 g / L.

[0041] The preparation method of the sophora japonica fruit composition for treating intestinal inflammation and protecting intestinal mucosa comprises the following steps: inoculating the fermented lactobacillus plantarum into a fermentation substrate containing the sophora japonica fruit, the citrus reticulata peel, the panax notoginseng, the momordica grosvenori and the flos lonicerae japonicae to obtain the traditional Chinese medicine composition for preventing and treating intestinal diseases.

[0042] The preparation method of the sophora japonica fruit composition for treating intestinal inflammation and protecting intestinal mucosa of the present application is to ferment the composition of the sophora japonica fruit, the citrus reticulata peel, the panax notoginseng, the momordica grosvenori and the flos lonicerae japonicae by using the lactobacillus plantarum, which does not need complicated process, can be used for large-scale production, and reduces cost and saves manpower.

[0043] In one of the embodiments, the inoculation amount of the fermented lactobacillus plantarum is 0.5-3 wt%.

[0044] In one of the embodiments, the fermentation substrate comprises the following components by weight percentage: the composition of the sophora japonica fruit, the citrus reticulata peel, the panax notoginseng, the momordica grosvenori and the flos lonicerae japonicae 80-98%, lecithin 1.9-17.5%, rhamnose glycoside 0.01-1%, dipotassium hydrogen phosphate 0.03-1% and magnesium sulfate 0.01-0.5%.

[0045] In one of the embodiments, the fermentation conditions of inoculating the fermented lactobacillus plantarum into the fermentation substrate containing the sophora japonica fruit, the citrus reticulata peel, the panax notoginseng, the momordica grosvenori and the flos lonicerae japonicae are as follows: mixing under 30-60% moisture, uniformly mixing and then fermenting at 25-35℃ for 5-7 days.

[0046] Use of the Sophora japonica composition for treating intestinal inflammation and protecting intestinal mucosa in any of the above described application in the preparation of health care products or medicines for treating intestinal inflammation and protecting intestinal mucosa.

[0047] The dosage form of the medicine or health care product is one of a tablet, a capsule, a granule, a powder or an oral liquid.

[0048] The Sophora japonica composition for treating intestinal inflammation and protecting intestinal mucosa of the present application can effectively inhibit the inflammation of colitis, and has a significant effect on intestinal microecological homeostasis, intestinal inflammation and intestinal mucosa protection of inflammatory bowel disease, and can be applied to various health care products and medicine fields for treating inflammatory bowel disease.

[0049] Example 1

[0050] A Sophora japonica composition for treating intestinal inflammation and protecting intestinal mucosa, comprising the following components: Sophora japonica, dried tangerine or orange peel, Panax notoginseng, Siraitia grosvenorii and day lily. The weight ratio of Sophora japonica:dried tangerine or orange peel:Panax notoginseng:Siraitia grosvenorii:day lily is 5:3:1.5:0.5:2.

[0051] A preparation method of a Sophora japonica composition for treating intestinal inflammation and protecting intestinal mucosa, comprising the following steps:

[0052] 1) Preparation of bacteria: a single colony is picked from a plate culture medium of Lactobacillus plantarum, inoculated into a liquid culture medium, and cultured at 30℃ and 200rpm for 48h. The bacteria are collected by centrifugation and the wet weight of the bacteria is determined.

[0053] The liquid culture medium comprises the following components: 10.0g / L of proteose peptone, 5.0g / L of corn starch, 5.0g / L of yeast powder, 2.0g / L of potassium phosphate dibasic, 5.0g / L of sodium acetate, 2.0g / L of diammonium hydrogen citrate, 0.2g / L of magnesium sulfate, and 0.054g / L of manganese sulfate. The culture medium is sterilized at 115℃ for 20min at a pH value of 6.0.

[0054] 2) Fermentation process: the bacteria obtained in step 1) are added to a fermentation substrate at an inoculation amount of 0.5wt%, the moisture is adjusted to 30%, and the mixture is uniformly mixed and fermented at 30℃ for 7 days. The fermented composition is dried by low-temperature cold air, crushed, and subjected to microbial sterilization treatment. The obtained material is the Sophora japonica composition for treating intestinal inflammation and protecting intestinal mucosa.

[0055] The fermentation substrate comprises the following components: 98% of the composition, 1.9% of lecithin, 0.5% of rhamnose glycosidase, 0.03% of potassium phosphate dibasic, and 0.01% of magnesium sulfate.

[0056] Example 2

[0057] A sophora japonica composition for treating intestinal inflammation and protecting intestinal mucosa, comprising the following components: sophora japonica, dried tangerine or orange peel, panax notoginseng, momordica grosvenori and lycium chinense. The weight ratio of sophora japonica:dried tangerine or orange peel:panax notoginseng:momordica grosvenori:lycum chinense is 5:2:2:1:1.

[0058] A preparation method of a sophora japonica composition for treating intestinal inflammation and protecting intestinal mucosa, comprising the following steps:

[0059] The bacteria obtained in Example 1 are added into the fermentation substrate at an inoculation amount of 3wt%, the moisture is adjusted to 45%, and then mixed thoroughly, and then the mixture is left to ferment at 25℃ for 6 days; the fermented composition is dried by low-temperature cold air, crushed, and subjected to certain microbial sterilization treatment, and the obtained substance is the sophora japonica composition for treating intestinal inflammation and protecting intestinal mucosa.

[0060] The fermentation substrate comprises the following components: composition 80%, lecithin 17.5%, rhamnose glycoside enzyme 1%, dipotassium hydrogen phosphate 0.485%, and magnesium sulfate 0.245%.

[0061] Example 3

[0062] A sophora japonica composition for treating intestinal inflammation and protecting intestinal mucosa, comprising the following components: sophora japonica, dried tangerine or orange peel, and lycium chinense. The weight ratio of sophora japonica:dried tangerine or orange peel:panax notoginseng:momordica grosvenori:lycum chinense is 6:5:1.5:1:2.

[0063] A preparation method of a sophora japonica composition for treating intestinal inflammation and protecting intestinal mucosa, comprising the following steps:

[0064] The bacteria obtained in Example 1 are added into the fermentation substrate at an inoculation amount of 1.75wt%, the moisture is adjusted to 60%, and then mixed thoroughly, and then the mixture is left to ferment at 35℃ for 5 days; the fermented composition is dried by low-temperature cold air, crushed, and subjected to certain microbial sterilization treatment, and the obtained substance is the sophora japonica composition for treating intestinal inflammation and protecting intestinal mucosa.

[0065] The fermentation substrate comprises the following components: composition 89%, lecithin 11%, rhamnose glycoside enzyme 0.01%, dipotassium hydrogen phosphate 1%, and magnesium sulfate 0.5%.

[0066] Example 4

[0067] A sophora japonica composition for treating intestinal inflammation and protecting intestinal mucosa, comprising the following components: sophora japonica, dried tangerine or orange peel, panax notoginseng, momordica grosvenori and lycium chinense. The weight ratio of sophora japonica:dried tangerine or orange peel:panax notoginseng:momordica grosvenori:lycum chinense is 4:3.5:1:1:3.

[0068] A preparation method of a sophora japonica composition for treating intestinal inflammation and protecting intestinal mucosa, comprising the following steps:

[0069] The bacteria obtained in Example 1 is added into the fermentation substrate with an inoculation amount of 0.5wt%, the moisture is adjusted to 30%, and the mixture is uniformly mixed and left to ferment at 30°C for 5 days. The fermented composition is dried by low-temperature cold air, crushed, and subjected to microbial sterilization treatment. The obtained material is a sophora fruit composition for treating intestinal inflammation and protecting intestinal mucosa.

[0070] The fermentation substrate comprises the following components: composition 95%, lecithin 4.5%, rhamnosidase 0.1%, dipotassium hydrogen phosphate 0.3%, and magnesium sulfate 0.1%.

[0071] Comparative Example 1

[0072] A traditional Chinese medicine composition comprises the following components: sophora fruit, dried tangerine or orange peel, panax notoginseng, momordica grosvenori, and flos lonicerae japonicae. The weight ratio of sophora fruit:dried tangerine or orange peel:panax notoginseng:momordica grosvenori:flos lonicerae japonicae is 6:5:1.5:1:2.

[0073] A preparation method of a traditional Chinese medicine composition comprises the following steps:

[0074] Sophora fruit, dried tangerine or orange peel, panax notoginseng, momordica grosvenori, and flos lonicerae japonicae are put into a container, and 10 times the weight of cold water of all the components is added for soaking for 20 minutes. The first decoction is performed by using a strong fire before boiling and a weak fire after boiling for 30 minutes. The second decoction is performed by adding 7 times the weight of cold water of all the components, and boiling for 15 minutes after boiling. The decoction is obtained by combining the two times of decoction.

[0075] Comparative Example 2

[0076] In Comparative Example 2, sophora fruit and dried tangerine or orange peel are not added, and the other components and the preparation method are the same as those in Example 1.

[0077] Comparative Example 3

[0078] In Comparative Example 3, sophora fruit and flos lonicerae japonicae are not added, and the other components and the preparation method are the same as those in Example 1.

[0079] Comparative Example 4

[0080] In Comparative Example 4, panax notoginseng and dried tangerine or orange peel are not added, and the other components and the preparation method are the same as those in Example 1.

[0081] Comparative Example 5

[0082] In Comparative Example 5, momordica grosvenori and flos lonicerae japonicae are not added, and the other components and the preparation method are the same as those in Example 1.

[0083] Performance test

[0084] 1. Animal experiment

[0085] Animal experiment procedures were performed according to the Chinese national guidelines. A total of 88 7-week-old female C57BL / 6N mice (16-18 g body weight) were housed in a specific pathogen-free animal room with constant temperature and humidity, and a 12-hour light / dark cycle. After 1 week of acclimation to the conditions, the mice were randomly divided into a control group, a DDS group, a group 1 (DDS + Example 1), a group 2 (DDS + Example 2), a group 3 (DDS + Example 3), a group 4 (DDS + Example 4), a group 5 (DDS + Comparative Example 1), a group 6 (DDS + Comparative Example 2), a group 7 (DDS + Comparative Example 3), a group 8 (DDS + Comparative Example 4), and a group 9 (DDS + Comparative Example 5), with 8 mice in each group. The control group: freely drank pure water, and was intragastrically administered pure water for 7 days. The DDS group: freely drank 1.5% DSS (dextran sulfate sodium) for 7 days. The treatment groups: freely drank 1.5% DSS, and were intragastrically administered the sophora fruit composition fermented by the fermented plant lactobacillus (1 mg / ml) for 7 days. At the end of the treatment period, the mice were anesthetized with isoflurane after fasting for 8 hours, and then the plasma, liver, colon, and cecum contents of the mice were immediately collected. All of the collected samples were stored at -80°C. Real-time fluorescent quantitative PCR was used to analyze the expression levels of the inflammatory factors interleukin 1β (IL-1β), interleukin 6 (IL-6), and tumor necrosis factor α (TNF-α); the interleukin 1β (IL-1β) gene expression amount is shown in Figure 1 , the interleukin 6 (IL-6) gene expression amount is shown in Figure 2 , the tumor necrosis factor α (TNF-α) gene expression amount is shown in Figure 3 ; the metabolism of the short-chain fatty acids acetate, propionate, and butyrate in the intestines was detected; the metabolism of the short-chain fatty acid acetate is shown in Figure 4 , the metabolism of the short-chain fatty acid propionate is shown in Figure 5 , and the metabolism of the short-chain fatty acid butyrate is shown in Figure 6 ; 16s ribosomal sequencing was performed on the intestinal contents to observe the number changes of Clostridia, Dubosiella, and Lactobacillus bacteria in the intestines; the number changes of the Lactobacillus bacteria are shown in Figure 7 , the number changes of the Dubosiella bacteria are shown in Figure 8 , and the number changes of the Clostridia bacteria are shown in Figure 9 .

[0086] As can be seen from Figures 1-3 , groups 1-4 significantly reduced the inflammation of the colon, as the mRNA gene expression levels of the inflammatory cytokines IL-1β, IL-6, and TNF-α were significantly reduced and were much lower than those of groups 5-9, indicating that the intestinal disease-preventing and -treating traditional Chinese medicine composition of the present application can effectively inhibit the inflammation level of colitis.

[0087] Depend on Figures 4-6 It can be seen that the amounts of short-chain fatty acid acetate, propionate and butyrate in groups 1-4 were significantly higher than those in groups 5-9 and the control group, indicating that the traditional Chinese medicine composition for preventing and treating intestinal diseases of the present invention can promote the metabolism of short-chain fatty acids in the intestine and increase the thickness of the intestinal mucosa.

[0088] Depend on Figures 7-9 It can be seen that the number of intestinal microorganisms Dubosiella and Lactobacillus in groups 1-4 was significantly higher than that in groups 5-9 and the control group, while the number of Clostridia was lower than that in groups 5-9 and the control group. This indicates that the traditional Chinese medicine composition for the prevention and treatment of enteropathy of the present invention has a significant therapeutic effect on the intestinal microecological homeostasis of inflammatory bowel disease.

[0089] 2. Study on the osmotic effect of the Sophora japonica flower composition in Caco-2 cells

[0090] The permeability of the Sophora japonica flower compositions of Examples 1-4 and the traditional Chinese medicine compositions of Comparative Examples 1-5 in Caco-2 cells was detected to predict the relative absorption rate of the compositions upon oral administration. Experimental groups: Group 1 (DDS + Example 1), Group 2 (DDS + Example 2), Group 3 (DDS + Example 4), Group 4 (DDS + Example 4), Group 5 (DDS + Comparative Example 1), Group 6 (DDS + Comparative Example 2), Group 7 (DDS + Comparative Example 3), Group 8 (DDS + Comparative Example 4), Group 9 (DDS + Comparative Example 5). A 500 μL aliquot of each solution was added to the top surface of Caco-2 cells cultured for 15 days, and 2000 μL of HBSS buffer was placed on the bottom surface of the cells. The cells were cultured at 37°C for 4 hours in an incubator. Afterwards, the culture medium was recovered from the top and bottom surfaces of the cells, and the permeability was measured. The permeability data are shown below. Figure 10 As shown.

[0091] Depend on Figure 10 It can be seen that the permeability of the Sophora japonica flower compositions in groups 1-4 is better than that of the traditional Chinese medicine compositions in groups 5-9, and the relative absorption rate of the Sophora japonica flower compositions in groups 1-4 is better, which is beneficial to human absorption.

[0092] In summary, the traditional Chinese medicine composition of Sophora japonica buds, dried tangerine peel, and daylily obtained by fermentation with Lactobacillus plantarum of the present invention can significantly inhibit intestinal inflammation, promote the metabolism of short-chain fatty acids in the intestine, and increase the thickness of the intestinal mucosa. It has significant therapeutic effects on intestinal microecological homeostasis, intestinal inflammation, and intestinal mucosal protection in inflammatory bowel disease.

[0093] The above merely illustrates the embodiments of the present application, and does not limit the patent scope of the present application, and any equivalent structure or equivalent process transformation, or direct or indirect application in other related technical fields, which are made by using the content of the present application specification and drawings, are also included in the patent protection scope of the present application.

Claims

1. A Sophora japonica flower composition for treating intestinal inflammation and protecting the intestinal mucosa, characterized in that, It is made from Sophora japonica buds, dried tangerine peel, Panax notoginseng, Siraitia grosvenorii and daylily, with the weight ratio of Sophora japonica buds, dried tangerine peel, Panax notoginseng, Siraitia grosvenorii and daylily being (4-6):(2-5):(1-2):(0.5-1):(1-3); The preparation method of the Sophora japonica flower composition includes the following steps: culturing and fermenting Lactobacillus plantarum to obtain fermented Lactobacillus plantarum; inoculating the fermented Lactobacillus plantarum into a fermentation substrate containing Sophora japonica flower, dried tangerine peel, Panax notoginseng, Siraitia grosvenorii and daylily at 30-60% moisture content; mixing evenly; and fermenting at 25-35℃ for 5-7 days to obtain the Sophora japonica flower composition. The inoculum amount of the fermented plant lactobacillus is 0.5-3 wt%; the fermentation substrate comprises the following components by weight percentage: 80-98% of a combination of Sophora japonica buds, dried tangerine peel, Panax notoginseng, Siraitia grosvenorii and daylily, 1.9-17.5% lecithin, 0.01-1% rhamnosidase, 0.03-1% dipotassium hydrogen phosphate and 0.01-0.5% magnesium sulfate.

2. The Sophora japonica flower composition for treating intestinal inflammation and protecting the intestinal mucosa according to claim 1, characterized in that, The weight ratio of Sophora japonica buds, dried tangerine peel, Panax notoginseng, Siraitia grosvenorii, and daylily is 5:3:1.5:0.5:

2.

3. The Sophora japonica flower composition for treating intestinal inflammation and protecting the intestinal mucosa according to claim 1, characterized in that, The plant lactobacillus is cultured and fermented in a liquid culture medium comprising the following components: peptone, corn starch, yeast powder, dipotassium hydrogen phosphate, sodium acetate, diammonium hydrogen citrate, magnesium sulfate, and manganese sulfate.

4. The use of the Sophora japonica flower composition for treating intestinal inflammation and protecting the intestinal mucosa as described in any one of claims 1 to 3 in the preparation of a medicament for treating intestinal inflammation and protecting the intestinal mucosa.

Images